Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.70, No.3, p. 476–484, 2023 |
||
| Title: Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study | ||
| Author: Tomislav Omrčen, Davor Eterović, Tea Jozić, Eduard Vrdoljak | ||
| Abstract: Six cycles of docetaxel in addition to androgen deprivation therapy (ADT) are currently one of the treatment options for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Since the outcomes in patients with high-volume (HV) disease remain modest, we aimed to identify patients for more intensified treatment. We report a cohort of 73 consecutive patients with de novo mHSPC treated with early docetaxel at the Department of Oncology and Radiotherapy, University Hospital of Split, Croatia, from October 2015 until March 2020. The outcomes analyzed were the occurrence of castration-resistant disease (CRPC) and death from any cause (OS). The median follow-up was 54 (50-73) months. Forty-six (63%) patients developed CRPC and 34 (47%) died during the follow-up. The median time to CRPC and median OS were 16.2 and 58.4 months, respectively. The risk of CRPC was higher for patients with high (above median) values of serum alkaline phosphatase (ALP) (HR=2.4; 95% CI [1.4–4.5]), lactate dehydrogenase (LDH) (HR=1.98; 95% CI [1.1–3.7]), prostate-specific antigen (PSA) (HR=1.8; 95% CI [1.1–3]), ECOG performance status >1 (HR=2; 95% CI [1.2–3.3]) and HV disease (HR=1.9; 95% CI [1.1–3.1]). The risk of any-cause death was higher in patients with high values of ALP, LDH, and ECOG performance status >1. The predictive value of LDH was independent of disease volume. A set of baseline characteristics could be used in conjunction with disease volume in deciding on the optimal treatment strategy for patients with de novo mHSPC. |
||
| Keywords: hormone-sensitive; prostate cancer; docetaxel; predictors | ||
| Published online: 25-Jul-2023 | ||
| Year: 2023, Volume: 70, Issue: 3 | Page From: 476, Page To: 484 | |
| doi:10.4149/neo_2023_221220N1190 |
||
|
|
 download file |
|